BioSpace News Archive

Together, the companies will focus on the generation of novel small molecule inhibitors against specified deubiquitinase (DUB) targets, specifically for the treatment of neurodegenerative and other diseases.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.

Recent reports revealed that the infection rates between adults and children were similar, but men are more likely to exhibit severe symptoms. The report also highlights the importance of contact tracing to help mitigate infection rates.

Bausch Health Companies Inc. and Ortho Dermatologics announced the U.S. Food and Drug Administration has approved a supplemental New Drug Application for JUBLIA® topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range included in the product’s label to children six years of age and older.

CytoSorbents Corporation announced that it has received $1,092,698, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.

Published Recently in the Journal of the American Academy of Dermatology

Oral presentations to include data on 4D-310 Product Candidate for Fabry Disease and 4D-A101 Aerosol Vector for Cystic Fibrosis and other Lung Diseases

Xeris Pharmaceuticals, Inc. announced it has extended its $0 copay offer for Gvoke™ Pre-Filled Syringe for commercially eligible patients effective through May 31, 2020 as a response to the COVID-19 pandemic.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the appointment of Sagar Lonial, MD, FACP, to the Company’s Board of Directors. Dr. Lonial has extensive experience in multiple myeloma and lymphoma treatment and research, and most recently has focused on developing combinations of novel agents for B-cell malignancies, particularly evaluating combinations that may result in synergistic inhibition of the PI3K/Akt pathway. He currently serves as P

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the close of U.S. financial markets on Monday, May 4, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate